Connect your AI

Novavax NVAX Finance Lease Liabilities

Finance Lease Liabilities at other companies

ModernaMRNA

$13M-62.9%

ImmunityBio, Inc.IBRX

$213K—

BioCryst PharmaceuticalsBCRX

$1.17M-49.3%

Other financials

Income statement

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

Market cap$1.46B+41.0%

Enterprise value$1.53B+83.6%

P/S2.5×+1.6×

Profitability

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Novavax's finance lease liabilities?: Novavax (NVAX) reported finance lease liabilities of $1.91M in Q1 2026.
How has Novavax's finance lease liabilities changed year-over-year?: Novavax's finance lease liabilities decreased by 96.4% year-over-year, from $53.06M to $1.91M.
What is the long-term trend for Novavax's finance lease liabilities?: Over 5 years (2020 to 2025), Novavax's finance lease liabilities has grown at a -44.6% compound annual growth rate (CAGR), from $40.08M to $2.09M.
What does finance lease liabilities mean?: Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.